ZINC stearate | 51731-04-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ZINC stearate
• 英文别名: zinc;octadecanoate
• CAS: 51731-04-5
• 化学式: Zn(C18H35O2)2
• 分子量: 632.3
• InChiKey: XOOUIPVCVHRTMJ-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  9.99
• 重原子数：
  41
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

锌主要与有机配体结合，而不是以阳离子形式自由存在于溶液中。血液中存在可扩散和不可扩散的锌形式，大约66%的血浆中可扩散形式的锌是自由交换的，并且松散地与白蛋白结合。少量不可扩散形式的锌在血浆中与α2-巨球蛋白紧密结合，并且不与其他锌配体自由交换。锌仅在肝脏中与α2-巨球蛋白结合和分离。/锌离子/

Zinc is mostly bound to organic ligands rather than free in solution as a cation. Zinc is found in diffusible and non-diffusible forms in the blood and about 66% of the diffusible form of zinc in the plasma is freely exchangeable and loosely bound to albumin. A small amount of the non-diffusible form of zinc is tightly bound to 2-macroglobulin in the plasma and is not freely exchangeable with other zinc ligands. Zinc is incorporated into and dissociated from alpha2-macroglobulin only in the liver. /Zinc ions/

来源:Hazardous Substances Data Bank (HSDB)

代谢

锌可以通过肺部、皮肤和胃肠道进入人体。肠道对锌的吸收由锌载体蛋白CRIP控制。锌还与金属硫蛋白结合，帮助防止过量锌的吸收。锌广泛分布并在所有组织和组织液中找到，特别是在肝脏、胃肠道、肾脏、皮肤、肺、大脑、心脏和胰腺中。在血液中，锌存在于红细胞中的碳酸酐酶结合，以及血浆中的白蛋白、α2-巨球蛋白和氨基酸结合。白蛋白和氨基酸结合的锌可以扩散穿过组织膜。锌通过尿液和粪便排出体外。

Zinc can enter the body through the lungs, skin, and gastrointestinal tract. Intestinal absorption of zinc is controlled by zinc carrier protein CRIP. Zinc also binds to metallothioneins, which help prevent absorption of excess zinc. Zinc is widely distributed and found in all tissues and tissues fluids, concentrating in the liver, gastrointestinal tract, kidney, skin, lung, brain, heart, and pancreas. In the bloodstream zinc is found bound to carbonic anhydrase in erythrocytes, as well as bound to albumin, _2-macroglobulin, and amino acids in the the plasma. Albumin and amino acid bound zinc can diffuse across tissue membranes. Zinc is excreted in the urine and faeces. (L49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

缺铁性贫血是由于锌的过量吸收抑制了铜和铁的吸收，这很可能是通过肠道粘膜细胞的竞争性结合实现的。铜和锌与铜锌超氧化物歧化酶的不平衡水平已被与肌萎缩侧索硬化症（ALS）联系在一起。胃酸能溶解金属锌，生成腐蚀性的氯化锌，这可能会对胃壁造成损害。金属烟雾热被认为是对吸入锌的免疫反应。（L48, L49, A49）

Anaemia results from the excessive absorption of zinc suppressing copper and iron absorption, most likely through competitive binding of intestinal mucosal cells. Unbalanced levels of copper and zinc binding to Cu,Zn-superoxide dismutase has been linked to amyotrophic lateral sclerosis (ALS). Stomach acid dissolves metallic zinc to give corrosive zinc chloride, which can cause damage to the stomach lining. Metal fume fever is thought to be an immune response to inhaled zinc. (L48, L49, A49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌性证据

A4；不可归类为人类致癌物。/硬脂酸盐（不包括有毒金属的硬脂酸盐）/

A4; Not classifiable as a human carcinogen. /Stearates (does not include stearates of toxic metals)/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌物分类

对人类无致癌性（未列入国际癌症研究机构IARC清单）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

长期接触锌会导致贫血、运动失调、乏力，并降低体内的好胆固醇水平。还认为它会导致胰腺和生殖损害。

Chronic exposure to zinc causes anemia, atazia, lethargy, and decreases the level of good cholesterol in the body. It is also believed to cause pancreatic and reproductive damage. (L49)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

该物质可以通过吸入其气溶胶被吸收进入人体。

The substance can be absorbed into the body by inhalation of its aerosol.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

吸收、分配和排泄

在未过量摄入锌的人类中，吸收的放射性标记锌的体内负担半衰期已被观察到，范围从162天到500天。在静脉给药65Zn2+后，半衰期范围从100天到500天。/锌离子/

In humans with no excessive intake of zinc, the body burden half-time of absorbed radio-labelled zinc has been observed to range from 162 to 500 days. After parenteral administration of 65Zn2+, half-times ranged from 100 to 500 days. /Zinc ions/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在一定的范围内，哺乳动物能够在低和高饮食锌摄入量时，维持总体的锌含量以及各种组织中生理所需的锌水平恒定。锌代谢的调节部位包括：从胃肠道吸收Zn2+，通过尿液排泄锌，与红细胞交换锌，组织释放锌以及向胃肠道分泌锌。胃肠道的吸收和分泌的调节可能对锌的体内平衡贡献最大。/锌离子/

Within certain limits, mammals can maintain the total body zinc and the physiologically required levels of zinc in the various tissues constant, both at low and high dietary zinc intakes. The sites of regulation of zinc metabolism are: absorption of Zn2+ from the gastrointestinal tract, excretion of zinc in urine, exchange of zinc with erythrocytes, release of zinc from tissue, and secretion of zinc into the gastrointestinal tract. Regulation of gastrointestinal absorption and gastrointestinal secretion probably contributes the most to zinc homeostasis. /Zinc ions/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  Zinc Oxide 、 丙烯酸 、 ZINC stearate 在 甲苯 作用下， 以 甲苯 为溶剂， 30.0~50.0 ℃ 、1.42 MPa 条件下， 反应 1.5h， 生成 Zinc acrylate
  参考文献：
  名称：

  Solid golf ball

  摘要：

  本发明提供了一种具有优异反弹特性和优异耐久性的实心高尔夫球。本发明涉及一种实心高尔夫球，包括一个核心和覆盖在核心上的覆盖层，所述核心是通过硫化和成型橡胶组成物获得的，其中所述橡胶组成物包含作为共交联剂的丙烯酸锌，其粒径分布为0.1至5μm，平均粒径为1至4.5μm。

  公开号：

  US06136906A1
• 作为产物：
  描述：

  硬脂酸 生成 ZINC stearate
  参考文献：
  名称：

  PETROVIC, S. M.;LONCAR, EVA, ZB. RAD., 18,(1987) C. 159-164

  摘要：

  DOI：
• 作为试剂：
  描述：

  锌 、 硬脂酸 在 ZINC stearate 、 水 作用下， 反应 0.92h， 以to obtain 100 g granular zinc stearate (melting point 120° C.)的产率得到ZINC stearate
  参考文献：
  名称：

  Method of producing granular metallic soap

  摘要：

  本发明涉及通过反应不溶于水的金属碳酸盐和脂肪酸来生产大颗粒的金属肥皂的方法。

  公开号：

  US04473504A1

文献信息

• [EN] SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS<br/>[FR] CARBOXAMIDES N-HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
  申请人：BIAL BIOTECH INVEST INC

  公开号：WO2021055627A1

  公开（公告）日：2021-03-25

  The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

  这项发明提供了替代的N-杂环羧酰胺和相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗疾病（例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病）的方法。
• [EN] PHOSPHODIESTERASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHODIESTÉRASE
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2009089027A1

  公开（公告）日：2009-07-16

  The invention relates to compounds of formula I useful for inhibiting phosphodiesterase-4.

  这项发明涉及到公式I的化合物，用于抑制磷酸二酯酶-4。
• PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY
  申请人：Rewcastle Gordon William

  公开号：US20110009405A1

  公开（公告）日：2011-01-13

  Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

  本文提供了式I的嘧啶基和1,3,5-三嗪基苯并咪唑化合物，以及它们的药物组合物、制备方法，以及作为抗癌治疗药物或药剂的用途，可以单独使用，也可以与放疗和/或其他抗癌药物联合使用。
• [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PFIZER

  公开号：WO2014068527A1

  公开（公告）日：2014-05-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

  本文披露了一种与Bruton's酪氨酸激酶（BTK）形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症，包括淋巴瘤，以及炎症性疾病或症状的方法。 (化学式I)
• [EN] ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES<br/>[FR] FORMULATIONS ORALES DE DÉRIVÉS DE PYRROLIDINE
  申请人：OBSEVA SA

  公开号：WO2015091365A1

  公开（公告）日：2015-06-25

  The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one- O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.

  本发明涉及固体口服制剂，包括化合物的配方(3Z,5S)-5-(羟甲基)-1-[(2'-甲基-1,1'-联苯基-4-基)羰基]吡咯烷-3-酮-O-甲氧肟，和/或其活性代谢物，并且涉及所述制剂在治疗和/或预防早产、早产、经前痛经和子宫收缩引起的胚胎着床失败中的使用。本发明还涉及其制备方法。

表征谱图